PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 8, 2026Allergology International0 citationsOpen Access

Outcomes following the discontinuation of biologic therapy in patients with severe asthma

View Full Paper
RTReoto TakeiHMHiroshi MatsumotoTITakashi Iwanaga

Key Points

  • This research aims to identify risk factors for exacerbations after stopping biologic therapy in severe asthma patients.
  • Examined baseline eosinophilia and sputum presence during therapy
  • Analyzed reasons for therapy discontinuation, including poor response and cost
  • Assessed risk factors in relation to asthma phenotypes and treatment classes
  • Baseline eosinophilia and persistent sputum are identified as significant risk factors
  • Exacerbations vary significantly based on asthma phenotype and treatment class
  • Careful patient selection is highlighted as crucial for managing therapy discontinuation

Abstract

Baseline eosinophilia, persistent sputum during therapy, and discontinuation prompted by poor response or cost may serve as risk factors for post-discontinuation exacerbations; however, risk is phenotype- and class-dependent. Careful patient selection and monitoring are essential when considering the discontinuation of biologic treatment.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Takei et al. (2026) studied this question.

synapsesocial.com/papers/698829520fc35cd7a884991dhttps://doi.org/10.1016/j.alit.2025.12.004
Ask AI
Helpful
Bookmark
Share
View Full Paper